A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers

• Published in: Scientific reports Vol. 8; no. 1; pp. 8217 - 11
• Main Authors: Fairus, Syed, Leow, Soon-Sen, Mohamed, Isa Naina, Tan, Yew-Ai, Sundram, Kalyana, Sambanthamurthi, Ravigadevi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.05.2018; Nature Publishing Group; Nature Portfolio
• Subjects: 692/163; 692/308/409; Biological activity; Cholesterol; Clinical trials; Gallic acid; Humanities and Social Sciences; Low density lipoprotein; multidisciplinary; Safety; Science; Science (multidisciplinary); Side effects; Supplements; Urine; Vegetable oils
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-26384-7

Plant phenolics are being increasingly consumed globally with limited scientific and clinical evidence pertaining to safety and efficacy. The oil palm fruit contains a cocktail of phenolics, and palm oil production results in high volumes of aqueous by-products enriched in phenolics and bioactives. Several lines of evidence from in vitro and in vivo animal studies confirmed that the aqueous extract enriched in phenolics and other bioactives collectively known as oil palm phenolics (OPP) is safe and has potent bioactivity. A phase one clinical trial was conducted to evaluate the safety and effects of OPP in healthy volunteers. In this single-blind trial, 25 healthy human volunteers were supplemented with 450 mg gallic acid equivalent (GAE)/day of OPP or control treatments for a 60-day period. Fasting blood and urine samples were collected at days 1, 30 and 60. Medical examination was performed during these trial interventions. All clinical biochemistry profiles observed throughout the control and OPP treatment period were in the normal range with no major adverse effect (AE) or serious adverse effect (SAE) observed. Additionally, OPP supplementation resulted in improvement of total cholesterol and LDL-C levels, compared to the control treatment. The outcomes support our previous observations that OPP is safe and may have a protective role in reducing cholesterol levels.